Section one: Contracting authority
one.1) Name and addresses
Medicines Discovery Catapult
Block 35, Mereside, Alderley Park
Cheshire
SK10 4TG
Contact
Mr Kieran McGowan
Kieran.McGowan@md.catapult.org.uk
Telephone
+44 1625708394
Country
United Kingdom
NUTS code
UKD62 - Cheshire East
Internet address(es)
Main address
Buyer's address
one.3) Communication
The procurement documents are available for unrestricted and full direct access, free of charge, at
https://procontract.due-north.com/RFx/RFxSummary?rfxId=2fb9a540-c5d8-eb11-810c-005056b64545
Additional information can be obtained from the above-mentioned address
Tenders or requests to participate must be submitted electronically via
https://procontract.due-north.com/RFx/RFxSummary?rfxId=2fb9a540-c5d8-eb11-810c-005056b64545
one.4) Type of the contracting authority
Other type
Research - Drug Discovery / Health
one.5) Main activity
Other activity
Research - Drug Discovery / Health
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
Logic Model and Impact Evaluation Methodology
Reference number
DN553327
two.1.2) Main CPV code
- 79000000 - Business services: law, marketing, consulting, recruitment, printing and security
two.1.3) Type of contract
Services
two.1.4) Short description
The Catapult Centres are a network of world-leading centres designed to transform the UK’s capability for innovation in specific areas and help drive future economic growth.
(https://catapult.org.uk/catapult-centres/). Our specific area is medicines discovery.
Part-funded by Innovate UK, an agency of the UK government, we are an independent not-for-profit company. We bring together industry, academia, charities, technologists, services, finance companies, SMEs and start-ups who together can turn good science into new, high-value products.
MDC is a national facility connecting the UK community to accelerate innovative drug discovery.
We provide unique scientific capabilities and act as a gateway to UK resources and expertise, supporting UK SMEs in developing new medicines discovery approaches.
By validating new ways of discovering medicines and driving key talent and expertise across the sector, we will support the UK life sciences industry, SMEs and innovators to deliver growth for the UK economy and maintain the UK’s heritage position as a global leader in medicines R&D.
MDC is currently in year 4 of our first 5-year grant funding agreement, referred to (GFA 1). To support our GFA1 evaluation, we have a logic model outlining our theory of change, and a supporting evaluation methodology framework, which we are in the process of implementing.
In parallel to the work we are delivering for GFA 1, Innovate UK has asked that we develop our logic model and evaluation methodology framework to support our next grant funding agreement, GFA 2.
The estimated value is between £20,000.00 and £35,000.00.
Link to ITT documents here: https://procontract.due-north.com/RFx/RFxSummary?rfxId=2fb9a540-c5d8-eb11-810c-005056b64545
two.1.6) Information about lots
This contract is divided into lots: No
two.2) Description
two.2.3) Place of performance
NUTS codes
- UKD62 - Cheshire East
two.2.4) Description of the procurement
The Catapult Centres are a network of world-leading centres designed to transform the UK’s capability for innovation in specific areas and help drive future economic growth.
(https://catapult.org.uk/catapult-centres/). Our specific area is medicines discovery.
Part-funded by Innovate UK, an agency of the UK government, we are an independent not-for-profit company. We bring together industry, academia, charities, technologists, services, finance companies, SMEs and start-ups who together can turn good science into new, high-value products.
MDC is a national facility connecting the UK community to accelerate innovative drug discovery.
We provide unique scientific capabilities and act as a gateway to UK resources and expertise, supporting UK SMEs in developing new medicines discovery approaches.
By validating new ways of discovering medicines and driving key talent and expertise across the sector, we will support the UK life sciences industry, SMEs and innovators to deliver growth for the UK economy and maintain the UK’s heritage position as a global leader in medicines R&D.
MDC is currently in year 4 of our first 5-year grant funding agreement, referred to (GFA 1). To support our GFA1 evaluation, we have a logic model outlining our theory of change, and a supporting evaluation methodology framework, which we are in the process of implementing.
In parallel to the work we are delivering for GFA 1, Innovate UK has asked that we develop our logic model and evaluation methodology framework to support our next grant funding agreement, GFA 2.
The estimated value is between £20,000.00 and £35,000.00.
Link to ITT documents here: https://procontract.due-north.com/RFx/RFxSummary?rfxId=2fb9a540-c5d8-eb11-810c-005056b64545
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £35,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
End date
31 October 2021
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
Section four. Procedure
four.1) Description
four.1.1) Type of procedure
Open procedure
four.1.8) Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: Yes
four.2) Administrative information
four.2.2) Time limit for receipt of tenders or requests to participate
Date
9 July 2021
Local time
12:00pm
four.2.4) Languages in which tenders or requests to participate may be submitted
English
four.2.6) Minimum time frame during which the tenderer must maintain the tender
Duration in months: 3 (from the date stated for receipt of tender)
four.2.7) Conditions for opening of tenders
Date
9 July 2021
Local time
12:05pm
Section six. Complementary information
six.1) Information about recurrence
This is a recurrent procurement: No
six.4) Procedures for review
six.4.1) Review body
Medicines Discovery Catapult
Block 35, Mereside, Alderley Park
Cheshire
SK10 4TG
kieran.mcgowan@md.catapult.org.uk
Country
United Kingdom